15
Bio Portfolio
Changes
There are no changes
Biotech Navigator, August 1997
gene fragments, vectors containing
tub gene sequences and host cells con-
taining tub genes and gene sequences.
It is believed the patent is the first the
office has granted covering a full-
length obesity gene.
The company's 1997 2
nd
quarter was hurt by higher than nor-
mal legal and other expenses primar-
ily associated with the ChemGenics
Pharmaceuticals Inc. merger, the for-
mation of the Whitehead functional
genomics consortium and the estab-
lishment of a unit, Millennium Bio-
Therapeutics Inc. Second quarter
earnings are a loss of 33 cents per
share compared to a loss of 19 cents a
share compared to 1996 second quar-
ter earnings.
Millennium reported earn-
ings on the 6 months ended June 30
th
,
to be a loss of $3.50 a share versus a
loss of 21 cents per share for the same
period in 1996. Earnings for 1997
include a of $83.8 million for ac-
quired in-process research and devel-
opment related to the ChemGenics
merger and about $1 million in amor-
tization expense. Before the charge, it
would have reported a loss of 47
cents a share.
Phase III clinical study of Ventus as a
treatment for acute respiratory dis-
tress. The company said a revised
pricing structure helped to increase
second quarter sales 23.8% compared
with the first quarter of the year. Li-
posome said it expects annualized
savings of about $8 million from its
recently completed restructuring.
The U.S. Patent and Trade-
mark Office granted
Millennium
(Issue #3-Prostate Cancer) a patent
covering tub genes, which may play a
role in causing obesity. The patent,
covers mammalian tub genes, tub
Aggressive Growth
Company
Recommendation
Date Price
7-30-97
Price
%
Change
Calypte (CALY)
2-28-97 8.25
5.88
-28.73
Cell Genesys (CEGE)
3-27-97 6.25
5.88
-5.92
Cytogen (CYTO)
4-30-97 4.94
4.63
-6.28
Digene (DIGE)
3-31-97 11.38
14.25
25.22
Intermediate Growth
Agouron (AGPH)
3-27-97 72.00
97.69
35.68
Cephalon (CEPH)
3-27-97 22.00
10.06
-54.21
Genset (GENXY)
6-30-97 19.38
22.88
18.06
Gilead (GILD)
3-27-97 24.88
28.50
14.55
Immune Response(IMNR) 3-27-97 8.50
8.63
1.53
Stable Growth
Amgen (AMGN)
3-27-97 57.75
59.75
3.41
Beckman (BEC)
3-27-97 43.00
48.69
13.23
Biogen (BGEN)
3-27-97 38.25
38.38
.34
Centocor (CNTO)
3-27-97 31.38
38.50
22.69
Chiron (CHIR)
3-27-97 18.88
20.88
10.59
Immunex (IMNX)
3-27-97 27.38
39.75
45.18
Incyte (INCY)
6-30-97 67.00
67.75
1.12
Liposome (LIPO)
3-27-97 23.06
7.63
-66.91
Millennium (MLNM)
3-27-97 16.38
15.00
-8.42
Genzyme (GENZ)
3-27-97 24.00
27.13
13.04
Genentech (GNE)
3-27-97 57.88
57.13
-1.30
Parexel (PRXL)
3-27-97 24.44
39.00
59.57
Perkin Elmer (PKU)
3-27-97 67.88
82.31
21.26
Quintiles (QTRN)
3-27-97 57.75
72.88
26.20
Company
Recommendation
Date Price
7-30-97
Price
Change
Hybridon (HYBN)
2-28-97 6.75
3.38
-49.93
Isis (ISIP)
3-27-97 16.25
13.25
-18.46
Supergen (SUPG)
3-27-97 11.13
13.75
23.54
Xoma (XOMA)
3-27-97 5.63
5.31
-5.68
